share_log

新天药业(002873.SZ)：战略投资参股公司汇伦医药，目前持股比例为14.88%

Xintian Pharmaceutical (002873.SZ): Strategically invested in Huilun Pharmaceutical, the current shareholding ratio is 14.88%

Gelonghui Finance ·  Apr 17 04:29

Gelonghui, April 17 | Xintian Pharmaceutical (002873.SZ) said on the investor interactive platform that the company's strategic investment in Huilun Pharmaceutical currently has a shareholding ratio of 14.88%. According to relevant accounting policy regulations, it has not yet been included in the scope of the company's consolidated statements, and changes in its operating performance will not have a significant impact on the company's 2023 net profit and other indicators. According to a thorough understanding of the business situation of Huilun Pharmaceutical Company, it is a high-tech enterprise dedicated to R&D and technical services for small molecule innovative drugs and generic drugs. The industrialization and commercialization process of its chemical products has been steady, and its business has grown rapidly in the past three years. From 2021 to 2023, as many products were launched and sold one after another, the revenue scale increased year by year, and achieved revenue of about 990 million yuan in 2023 (data is being audited). Its core product, the injectable cevilestana single product, has been produced on a large scale, and is its main performance contributor; in addition, Huilun Pharmaceutical achieved a profit of more than 30 million yuan in 2023 (data is being audited), and achieved independent cash flow, reflecting the growth of its commercialization process.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment